Evidence map›Paper›PMID 42279172›Full record

ArticleJournal of clinical medicine2026

Molecular Evaluation of RNA-Based Immune Checkpoint Profiling in Clear Cell Renal Cell Carcinoma.

Erica Giacobbi, Valeria Palumbo, Francesca Servadei, Rita Bonfiglio, Giusella Maria Francesca Moscato, Marco Carilli, Matteo Vittori, Valerio Iacovelli, Pierluigi Bove, Alessandro Mauriello and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Erica GiacobbiDepartment of Experimental Medicine, Torvergata Oncoscience Research (TOR), University of Rome Tor Vergata, 00133 Rome, Italy.
Valeria PalumboDepartment of Experimental Medicine, Torvergata Oncoscience Research (TOR), University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0001-7756-6676
Francesca ServadeiDepartment of Experimental Medicine, Torvergata Oncoscience Research (TOR), University of Rome Tor Vergata, 00133 Rome, Italy.
Rita BonfiglioDepartment of Experimental Medicine, Torvergata Oncoscience Research (TOR), University of Rome Tor Vergata, 00133 Rome, Italy.
Giusella Maria Francesca MoscatoDepartment of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
Marco CarilliUrology Unit, Department of Surgery, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0002-2416-9762
Matteo VittoriUrology Unit, Department of Surgery, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0002-5597-2742
Valerio IacovelliUrology Unit, Department of Surgery, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0001-5138-3177
Pierluigi BoveUrology Unit, Department of Surgery, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0002-4788-2982
Alessandro MaurielloDepartment of Experimental Medicine, Torvergata Oncoscience Research (TOR), University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0002-7351-5676
Manuel ScimecaDepartment of Experimental Medicine, Torvergata Oncoscience Research (TOR), University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0003-0585-1309

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

clear cell renal carcinomaimmune checkpointsimmunotherapiesprecision medicine

Identifiers

PMID42279172
PMCPMC13258794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.